skip to Main Content

Mental Illness Research Wins Award

  • This page as PDF


Findings from a new Avalere study, titled “Prevalence and Likelihood of Hospital Admission and Readmission in Patients with Serious Mental Illness,” were presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific conference on Sunday, September 9, 2018.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

The presentation won a Research Presentation Award. Only the top 10% of accepted research abstracts, based on peer review scoring, are eligible for the award.

The study, conducted by the Avalere Health Economics and Advanced Analytic team, evaluates the prevalence and likelihood of all-cause and psychiatric hospital admission in patients with serious mental illness (SMI), including bipolar disorder, major depressive disorder, and schizophrenia. The study findings provide new information to help providers better understand which patients with SMI are at greatest risk for hospital admission and readmission to better develop interventions designed to reduce these adverse and costly events.

The study’s primary findings include:

  • Women and newly diagnosed patients aged ≤45 were less likely to be hospitalized compared with men and patients aged 46–65 years.
  • Patients with SMI aged 26–45 with a recent hospitalization had the highest likelihood of readmission.
  • Patients with Medicaid or commercial insurance were more likely to be hospitalized following diagnosis compared to those covered by Medicare, but they were less likely to be readmitted.
  • The higher rate of hospitalizations may be due to greater burden of illness in the older Medicare Advantage (MA) population, while the lower rate of readmissions among Medicare patients may be related to the coordinated care and additional benefits provided by MA plans.

The study was supported by data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry®.

To learn more about our research capabilities, connect with us.

Funding for this study was provided by Otsuka Pharmaceutical.

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about RWE and Patient-Centered Outcomes
Please enter your email address to be notified when new RWE and Patient-Centered Outcomes insights are published.

Back To Top